CART-TM4SF1

N/A

Report date: 2025/01/26 19:11:46

Base Information

Drug NameCART-TM4SF1
Drug Alias Nameanti-TM4SF1 CAR-T cell therapy (Shanghai Ultra-T Immune Therapeutics/Changhai Hospital)TM4SF1-positive chimeric antigen receptor T-cell therapyCART-TM4SF1
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionTransmembrane 4 L6 family member 1 inhibitors
TargetsTransmembrane 4 L6 family member 1
Therapy Area/IndicationsPancreatic NeoplasmsLiver NeoplasmsStomach Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesChanghai Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Keqi Pharmaceutical Technology Co LtdChanghai Hospital
Inactive CompaniesN/A
Active IndicationsPancreatic NeoplasmsLiver NeoplasmsStomach Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A